Zoetis Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Zoetis Inc 公司

Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).

Zoetis Inc簡介



公司代碼ZTS

公司名稱Zoetis Inc

上市日期Feb 01, 2013

CEOPeck (Kristin C)

員工數量13800

證券類型Ordinary Share

年結日Feb 01

公司地址10 Sylvan Way

城市PARSIPPANY

上市交易所NASDAQ OMX NASDAQ Basic NYSE

國家United States of America

郵編07054

電話19738227000

網址https://www.zoetis.com/

公司代碼ZTS

上市日期Feb 01, 2013

CEOPeck (Kristin C)

Zoetis Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Ms. Kristin C. Peck

Chief Executive Officer, Director

105.88K

+10.27%

Mr. Gregory (Greg) Norden

Independent Director

16.95K

-7.15%

Ms. Louise M. Parent

Independent Director

16.26K

+6.17%

Mr. Sanjay Khosla

Independent Director

9.81K

--

Dr. Robert J. (Rob) Polzer, Ph.D.

Executive Vice President, President - Research and Development

6.19K

+0.39%

Ms. Rimma Driscoll

Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices

5.71K

+9.15%

Ms. Vanessa Broadhurst

Independent Director

3.92K

+28.11%

Mr. Jamie Brannan

Executive Vice President, Chief Commercial Officer

3.71K

+30.18%

Mr. Keith Sarbaugh

Executive Vice President, Chief Digital and Technology Officer

3.35K

+30.01%

Mr. Nicholas (Nick) Ashton

Executive Vice President, President - Global Manufacturing and Supply

1.82K

+39.96%

名稱

名稱/職務

職務

持股

持股變動

Ms. Kristin C. Peck

Chief Executive Officer, Director

105.88K

+10.27%

Mr. Gregory (Greg) Norden

Independent Director

16.95K

-7.15%

Ms. Louise M. Parent

Independent Director

16.26K

+6.17%

Mr. Sanjay Khosla

Independent Director

9.81K

--

Dr. Robert J. (Rob) Polzer, Ph.D.

Executive Vice President, President - Research and Development

6.19K

+0.39%

Ms. Rimma Driscoll

Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices

5.71K

+9.15%

收入明細

單位: USD更新時間: 4月6日週一

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

Parasiticides

2.34B

24.73%

Vaccines

1.96B

20.69%

Dermatology

1.75B

18.53%

Anti-infectives

1.04B

10.94%

Pain and sedation

840.00M

8.87%

其他

1.54B

16.24%

地區USD

名稱

營收

佔比

United States

5.10B

53.84%

Other emerging markets

913.00M

9.64%

Other Developed

641.00M

6.77%

Brazil

393.00M

4.15%

Australia

329.00M

3.48%

其他

2.09B

22.12%

業務

地區

業務USD

名稱

營收

佔比

Parasiticides

2.34B

24.73%

Vaccines

1.96B

20.69%

Dermatology

1.75B

18.53%

Anti-infectives

1.04B

10.94%

Pain and sedation

840.00M

8.87%

其他

1.54B

16.24%

股東統計

更新時間: 2月19日週四

持股股東

股東類型

持股股東

佔比

The Vanguard Group, Inc.

11.31%

BlackRock Institutional Trust Company, N.A.

5.66%

State Street Investment Management (US)

4.71%

State Farm Insurance Companies

4.01%

Wellington Management Company, LLP

2.71%

其他

71.60%

持股股東

佔比

The Vanguard Group, Inc.

11.31%

BlackRock Institutional Trust Company, N.A.

5.66%

State Street Investment Management (US)

4.71%

State Farm Insurance Companies

4.01%

Wellington Management Company, LLP

2.71%

其他

71.60%

股東類型

持股股東

佔比

Investment Advisor

51.44%

Investment Advisor/Hedge Fund

33.45%

Research Firm

4.15%

Insurance Company

4.10%

Pension Fund

2.98%

Bank and Trust

2.62%

Hedge Fund

1.45%

Sovereign Wealth Fund

1.45%

Individual Investor

0.08%

機構持股



更新時間: 4月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2026Q4

2795

428.61M

99.51%

--

2026Q1

3338

427.05M

101.16%

-14.43M

2025Q4

3335

436.13M

98.96%

-14.08M

2025Q3

3275

435.62M

98.29%

-1.39M

2025Q2

3277

434.35M

98.00%

-1.58M

2025Q1

3284

432.42M

97.12%

-4.21M

2024Q4

3199

430.60M

96.14%

-9.58M

2024Q3

3090

434.14M

95.81%

-13.19M

2024Q2

3062

437.75M

95.94%

-9.33M

2024Q1

3060

439.45M

96.16%

-2.63M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

47.57M

11.27%

+5.47M

+12.99%

Dec 31, 2025

BlackRock Institutional Trust Company, N.A.

23.78M

5.63%

+982.47K

+4.31%

Dec 31, 2025

State Street Investment Management (US)

19.80M

4.69%

+149.38K

+0.76%

Dec 31, 2025

State Farm Insurance Companies

16.88M

4%

+9.70K

+0.06%

Dec 31, 2025

Wellington Management Company, LLP

11.39M

2.7%

+2.85M

+33.41%

Dec 31, 2025

Geode Capital Management, L.L.C.

11.33M

2.68%

+189.24K

+1.70%

Dec 31, 2025

Morgan Stanley Investment Management Ltd. (UK)

6.65M

1.58%

-827.17K

-11.06%

Dec 31, 2025

Norges Bank Investment Management (NBIM)

5.84M

1.38%

+646.40K

+12.45%

Dec 31, 2025

Polen Capital Management, LLC

5.56M

1.32%

-1.95M

-26.00%

Dec 31, 2025

Nordea Funds Oy

4.93M

1.17%

+2.18M

+79.17%

Dec 31, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

ProShares Pet Care ETF

9.4%

VanEck Pharmaceutical ETF

9.02%

VanEck Agribusiness ETF

7.81%

iShares U.S. Pharmaceuticals ETF

4.26%

Honeytree US Equity ETF

3.86%

First Trust NASDAQ Pharmaceuticals ETF

3.58%

Polen Capital Global Growth ETF

3.35%

State Street SPDR S&P Pharmaceuticals ETF

2.51%

AAM Sawgrass US Large Cap Quality Growth ETF

2.47%

Themes US R&D Champions ETF

1.96%

ProShares Pet Care ETF

佔比9.4%

VanEck Pharmaceutical ETF

佔比9.02%

VanEck Agribusiness ETF

佔比7.81%

iShares U.S. Pharmaceuticals ETF

佔比4.26%

Honeytree US Equity ETF

佔比3.86%

First Trust NASDAQ Pharmaceuticals ETF

佔比3.58%

Polen Capital Global Growth ETF

佔比3.35%

State Street SPDR S&P Pharmaceuticals ETF

佔比2.51%

AAM Sawgrass US Large Cap Quality Growth ETF

佔比2.47%

Themes US R&D Champions ETF

佔比1.96%

分紅派息



近5年累計派現 2.56B 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

Feb 05, 2026

ZTS.NB Interim Cash Dividend of gross USD 0.53 paid on Jun 02, 2026 going ex on Apr 20, 2026

Apr 20, 2026

Jun 02, 2026

Apr 20, 2026

Dec 11, 2025

ZTS.NB Interim Cash Dividend of gross USD 0.53 paid on Mar 03, 2026 going ex on Jan 20, 2026

Jan 20, 2026

Mar 03, 2026

Jan 20, 2026

Oct 09, 2025

ZTS.NB Final Cash Dividend of gross USD 0.5 paid on Dec 02, 2025 going ex on Oct 31, 2025

Oct 31, 2025

Dec 02, 2025

Oct 31, 2025

May 21, 2025

ZTS.NB Interim Cash Dividend of gross USD 0.5 paid on Sep 03, 2025 going ex on Jul 18, 2025

Jul 18, 2025

Sep 03, 2025

Jul 18, 2025

Feb 06, 2025

ZTS.NB Interim Cash Dividend of gross USD 0.5 paid on Jun 03, 2025 going ex on Apr 21, 2025

Apr 21, 2025

Jun 03, 2025

Apr 21, 2025

Dec 12, 2024

ZTS.NB Interim Cash Dividend of gross USD 0.5 paid on Mar 04, 2025 going ex on Jan 21, 2025

Jan 21, 2025

Mar 04, 2025

Jan 21, 2025

Oct 10, 2024

ZTS.NB Final Cash Dividend of gross USD 0.432 paid on Dec 03, 2024 going ex on Oct 31, 2024

Oct 31, 2024

Dec 03, 2024

Oct 31, 2024

May 22, 2024

ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Sep 04, 2024 going ex on Jul 18, 2024

Jul 18, 2024

Sep 04, 2024

Jul 18, 2024

Feb 06, 2024

ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Jun 04, 2024 going ex on Apr 18, 2024

Apr 19, 2024

Jun 04, 2024

Apr 18, 2024

Dec 07, 2023

ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Mar 01, 2024 going ex on Jan 18, 2024

Jan 19, 2024

Mar 01, 2024

Jan 18, 2024

拆合股



公告日期

除權除息日

類型

比率

暫無數據

公告日期

除權除息日

類型

比率

暫無數據